

DIASORIN OBTAINED FDA APPROVAL FOR THE FIRST FULLY AUTOMATED LABORATORY SEROLOGY TESTS FOR HUMAN PARVOVIRUS B19 IgM AND HUMAN PARVOVIRUS B19 IgG ON THE LIAISON XL.

THE NEW LIAISON BIOTRIN PARVOVIRUS B19 IgM PLUS AND IgG PLUS ASSAYS WILL:

- ADDRESS A SIGNIFICANT GAP IN FDA-APPROVED AUTOMATED PARVOVIRUS TESTING, EXPANDING ACCESS THROUGH THE LIAISON FAMILY OF ANALYZERS;
- PROVIDE SAME-DAY TEST RESULTS, ENABLING FASTER DIAGNOSIS AND MORE TIMELY TREATMENT AND PATIENT GUIDANCE.

Saluggia, Italy – October 13, 2026 – Diasorin (DIA:MI) announced today it has obtained U.S. Food and Drug Administration (FDA) approval for the first fully automated diagnostic tests for Parvovirus B19 serology on the Diasorin LIAISON XL immunoassay system.

This approval marks another milestone in Diasorin's history of delivering first-to-market solutions that advance innovation and accelerate patient results. The fully automated LIAISON Biotrin Parvovirus B19 IgM Plus and the LIAISON Biotrin Parvovirus B19 IgG Plus assays on the Diasorin LIAISON XL are available in the United States.

Human Parvovirus B19 is a highly contagious erythrovirus transmitted primarily through respiratory droplets and close person-to-person contact. Infection may result in serious complications in pregnant women, immunocompromised individuals, and patients with chronic hemolytic disorders.

Human Parvovirus B19 (fifth disease) is diagnosed serologically through detection of specific IgM antibodies for active infections and IgG antibodies which indicate previous exposure and immune status. Maternal infection can cross the placenta (approximately in 30-50% of cases), potentially causing severe fetal anemia, hydrops fetalis (fatal swelling), miscarriage, or stillbirth. While most infected pregnancies result in favorable outcomes, high-risk cases may require intrauterine blood transfusion.

"Because maternal Parvovirus B19 infection may result in serious fetal complications, timely serological testing of exposed pregnant women is critical to assess immune status, identify recent infection, and support appropriate clinical follow-up", Gabriele Allegri, Diasorin President, Immuno Division. "We are excited to bring in another first automated testing solution to offer our clinicians same day results."

About Diasorin

Headquartered in Italy and listed on Euronext Milan, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Margherita Sacerdoti

Senior Director Investor Relations & ESG

margherita.sacerdoti@diasorin.com